Navigation Links
NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan

opment at NicOx, commented: "This ambitious project, jointly conducted by Axcan and NicOx aimed to develop an efficacious treatment for portal hypertension, a life threatening complication of chronic liver disease. This indication represents a major therapeutic challenge as the processes of the disease are not well understood and there are currently no treatments available. Unfortunately, NCX 1000 did not demonstrate the efficacy required to justify further development, although we are pleased that the safety and tolerability of the product were good."

NOTE: Portal hypertension is the most common manifestation of chronic liver disease and is responsible for the majority of the morbidity and mortality related to this disorder. The condition is caused by increased resistance to blood flow through the liver due to structural and blood flow changes. Consequently, blood is forced to return to the heart using other vessels, which are not adapted to high pressure and therefore rupture, causing life threatening bleeding.

NicOx (Bloomberg: COX; FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development of nitric oxide- donating drugs to meet unmet medical needs. NicOx is targeting the therapeutic areas of pain and inflammation and cardio-metabolic disease. Resources are focused on two lead compounds, naproxcinod (formerly HCT 3012); in phase 3 development for the treatment of the signs and symptoms of osteoarthritis, and NCX 4016, in phase 2 for type 2 diabetes.

NicOx has strategic partnerships with some of the world's leading pharmaceutical companies, including Pfizer Inc. and Merck and Co., Inc.

NicOx S.A. is headquartered in Sophia-Antipolis, France, and is a public company listed on the Eurolist of Euronext(TM) Paris (segment: Next Economy).

The elements included in this communication may contain forward-looking statements subject to certain risks and uncertainties. Actual results of the company may
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NicOx Provides Update the Phase Study for NCX Conducted With Axcan
(Date:5/22/2013)... GROVE, Minn. , May 22, 2013 ... announced the successful completion of its global ... topiramate), an internally developed program for the ... company,s proprietary formulation technology.  USL255 is specifically ... reduce fluctuations in topiramate blood levels observed ...
(Date:5/22/2013)... , May 22, 2013  Generex Biotechnology Corporation ... demonstrating the superiority of the AE37 breast cancer vaccine ... ( www.antigenexpress.com ). The presentations will be made at ... Oncology (ASCO) to be held in Chicago ... The presentation entitled " Booster inoculations of ...
(Date:5/22/2013)...  Grifols, ein globales Unternehmen der Gesundheitsbranche ... , Spanien, präsentierte die Ergebnisse einer Studie, ... PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel des Alpha1-Proteins ... Niveau anhebt, das innerhalb des für gesunde ... eine lebensbedrohliche, genetische Erkrankung, bei der der ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4
(Date:5/22/2013)... that hospitals may be reaping enormous income for ... bloodstream infections contracted in their intensive care units. ... in the American Journal of Medical Quality ... who develops an avoidable central line-associated bloodstream infection ... for than a similar infection-free patient. Moreover, hospitals ...
(Date:5/22/2013)... 22, 2013 Recent tragedies including ... the school shooting in Newtown, Connecticut all resulted ... , Emergency medical practitioners train to respond ... Emergency Medical Services for Children (EMSC) Program specifically ... for the youngest patients. It is estimated 30 ...
(Date:5/22/2013)... 22, 2013 Space Girl Organics ... sponsor for this weekend's I Talk to Strangers Miracle ... am at Cocoa Riverside Park in Cocoa, FL. The event ... Talk to Strangers social movement. , As a sponsor, Space ... to participate in the event. Additionally, they are providing bananas ...
(Date:5/22/2013)... Pamela Isom, President and CEO of ICE ... 2013 Women of Influence Award in recognition for her ... reception took place on Thursday, May 2 at The ... particularly humbling for the 5,000 people ICE Safety Solutions ... to recognize the four to nine lives saved per ...
(Date:5/22/2013)... 2013 Homeopathic Vibes is implementing new store ... to the store during normal hours. On Wednesdays, they will ... to accommodate some of our patients who work shifts that ... or on Saturdays,” says owner and homeopathic consultant, Harminder Singh. ... 6 p.m. Monday through Friday; weekends are by appointment only. ...
Breaking Medicine News(10 mins):Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:When Tragedies Impact Children – Kentucky Emergency Medical Services for Children (KYEMSC) Offers Specialized Training for Pediatric Emergency Care 2Health News:Space Girl Organics to Sponsor May 25 Miracle Run/Walk 2Health News:Pamela Isom, President and CEO of ICE Safety Solutions Inc. Receives 2013 Women of Influence Recognition and Award 2Health News:Homeopathic Vibes Now Open Late on Wednesdays 2
... YORK, NY, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - ... acquires, and develops novel drug targets that disrupt the ... a patent for a potential blockbuster drug target that ... a tailor-made lipid which induces cell death in breast ...
... Immediately after President Obama,s speech to a Joint Session of ... nation,s top political, legislative and communications strategists -- representing a ... and public relations. , , The ... very happy with the speech, but most reactions were short ...
... ... rights to a suite of intellectual property owned by Spherofix AB. , ... Charlotte, NC (PRWEB) September 10, ... acquired exclusive rights to a suite of intellectual property owned by Spherofix AB., , ...
... Netherlands, September 10 The Danish Council,for Strategic Research ... Thursday, September 10. The purpose of their visit is ... and the concrete results,that are being booked by this ... cited TI Pharma as a prime example of public-private,collaboration ...
... Sept. 9 Family Research Council President Tony Perkins made ... a joint session of Congress. , , ... , Tomorrow night in a live webcast at ... address. Perkins will be joined by Senator Jim DeMint (R-SC), ...
... , WASHINGTON, Sept. 9 America,s ... Ignagni, President and CEO: , , "We agree ... plans last year did something industries rarely do: stepped up and ... American people. We proposed health insurance reform to guarantee coverage ...
Cached Medicine News:Health News:GENova files patent for new breast cancer treatment 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 2Health News:Clarus Research Group Survey: Top Political Strategists React to Obama's Health Care Speech, Rate Effectiveness 3Health News:Kapstone Medical Acquires Exclusive License to New Orthopedic Technology 2Health News:Dutch Top Institute Pharma Attracts International Interest 2Health News:President Obama's Campaign Style Speech Points to a Health Care Plan on Life Support 2
... range of diagnosis by using the Convex Scanning ... clear image of blood flow by using the ... accessory elevator has been incorporated and the balloon ... for more advanced and accurate techniques. The FG-36UX ...
... ACL 10000 allows you to maximize your ... staff are limited. This fully automated system ... analysis and advanced robotics, to ensure testing ... the ACL 10000 is backed by our ...
The SYNCHRON CX7-S workstation offers a broad menu, advanced data management and more. Targeted to the mid-volume lab, the CX7-S is easy to use, easy to maintain and easy to acquire....
... CX5 Delta takes the automation and ... and adds the benefit of electrolyte ... chemistry system for the low- to ... capabilities and continuous sample loading. The ...
Medicine Products: